Scholar-in-Training Awards: Annual Meeting
Since its inception in 1986, the AACR Annual Meeting Scholar-in-Training Award program has provided almost 4,700 grants to young investigators and has received support from 60 cancer research foundations, corporations, individuals, and other organizations dedicated to the fight against cancer.
Scholar-in-Training Awards are highly competitive and recognize outstanding young investigators presenting meritorious proffered papers at the AACR Annual Meeting.
The deadline to submit all applications for Scholar-in-Training Awards for the AACR Annual Meeting 2021 is November 19, 2020.Submit Application
- Applicants must be the first author and presenter of an abstract submitted for presentation at the Annual Meeting.
- Applicants must be an Associate Member of the AACR in good standing (membership current through 2020). Nonmember graduate students, medical students and residents, clinical fellows or equivalent, and postdoctoral fellows who wish to apply for a Scholar-in-Training Award should submit a Membership Application Form by November 12, 2020 in order to obtain membership in time to then submit an application for a Scholar-in-Training Award.
- Applicants cannot be employees or subcontractors of for-profit private industry.
- Applicants may apply for other awards, but may only receive one award from the AACR to attend the Annual Meeting.
- We encourage applications from all areas of cancer research. Scholar-in-Training Awards funded by certain supporters are restricted to certain types of cancer research. Currently, in addition to general funding, the AACR has received funding for extra 2021 Annual Meeting Scholar-in-Training Awards in chemistry or breast cancer. This list will be updated with any areas of cancer research for which the AACR has received additional funds.
If you have any questions related to Scholar-in-Training Awards for the Annual Meeting, please email us at [email protected].
Congratulations to the 2020 Annual Meeting Scholar-in-Training Awardees!
The names and affiliations of the 2020 Scholar-in-Training Award recipients, along with the abstract numbers and titles of their abstracts, are listed below.
Ziena Abdulrahman, MS, Leiden University Medical Center, Leiden, The Netherlands. Abstract 1582. A pre-existing inflammatory immune microenvironment predicts the clinical and immunologic response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 peptide vaccination.
Kristin Ann Altwegg, MS, UT Health San Antonio, San Antonio, Texas. Abstract 6403. Characterization of small-molecule inhibitors of PELP1 for treating advanced breast cancer.
Alfonso E. Bencomo, PhD, Texas Tech University Health Science Center El Paso, El Paso, Texas. Abstract 4343. Retrospective study of incidence and survival for patients with hematologic malignancies residing at the U.S./Mexico border.
Davide Bernareggi, PhD, University of California San Diego, San Diego, California. Abstract CT053. Use of CRISPR knock-out screen to identify genes that regulate tumor cell sensitivity to NK cell-based immunotherapy.
Vrushank Dharmesh Bhatt, MS, Rutgers University, New Brunswick, New Jersey. Abstract 5710. Autophagy inhibition sensitizes Liver Kinase B1 (LKB1)-deficient Kras-driven lung tumors to MEK inhibitor trametinib.
M. Emma G. Bigelow, BS, Johns Hopkins School of Medicine, Baltimore, Maryland. Abstract 5670. Machine learning methods to identify salient genomic predictors of clinical responses to immune checkpoint inhibitor therapy.
Kaouthar Bouzinab. MSc, University of Nottingham, Nottingham, United Kingdom. Abstract 1727. Challenging resistance to temozolomide in glioblastoma by drug encapsulation in apoferritin.
Nathaniel Boyd, PhD, Emory University School of Medicine, Atlanta, Georgia. Abstract 3789. Therapeutic targeting of the YAP/TAZ pathway in glioblastoma with verteporfin.
Galabina Bozhanova, BSc (Hons), The Institute of Cancer Research, London, United Kingdom. Abstract 3415. Mutant BRAF small-molecule inhibition enhances oncolytic herpes virus immunotherapy through increased immune cell recruitment and activation in melanoma.
Matthias Bozza, PhD, DKFZ Heidelberg, Heidelberg, Germany. Abstract 4066. A nonintegrating, nonviral DNA nanovector platform for the safe, persistent, and rapid manufacture of recombinant T-cells for adoptive cell therapy.
Andrä Brunner, MSc, Karolinska Institute, Stockholm, Sweden. Abstract 2371. FBXL12 modulates Fanconi anemia-BRCA signaling under conditions of oncogene-induced replication stress.
Antonino Bruno, PhD, IRCCS MultiMedica, Milan, Italy. Abstract 1581. Prostate tumor-associated NK cells (PTANKs) acquire the decidual-like/proangiogenic phenotype and polarize macrophages towards the M2-like/TAM subset.
Thomas Callender, MBChB, MSc, University College London, London, United Kingdom. Abstract 3523. MRI-first screening for prostate cancer: A benefit-harm and cost-effectiveness analysis.
Nathaniel R. Campbell, MS, Memorial Sloan Kettering Cancer Center, New York, New York. Abstract 1107. Cell state diversity promotes metastasis through heterotypic cluster formation in melanoma.
Jason E. Chan, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, New York. Abstract 1511. A highly plastic cell state emerges during lung adenocarcinoma evolution.
Benjamin C. Chandler, BS, University of Michigan, Ann Arbor, Michigan. Abstract 6273. TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination.
Anil Chandra, PhD, Institute of Nanotechnology (CNR Nanotec), Lecce, Italy. Abstract 2967. Microgel-based in vitro tumoroid platform for real-time assessment of drug sensitivity and resistance.
Akshaya Chandrasekaran, PhD, Brigham and Women’s Hospital, Boston, Massachusetts. Abstract 6241. PAX8-directed nanotherapeutics for high-grade serous ovarian carcinoma.
Mei-Kuang Chen, MS, The University of Texas MD Anderson Cancer Center, Houston, Texas. Abstract 5682. Synergism of PARP inhibitor and MET inhibitor in multiple cancer types with intrinsic and acquired PARP inhibitor resistances.
Caleb Cheng, BS, University of Michigan, Ann Arbor, Michigan. Abstract 1278. Elucidating the mechanistic role of ERG in prostate cancer.
Taek-Chin Cheong, PhD, Boston Children’s Hospital and Harvard Medical School, Boston, Massachusetts. Abstract 2393. APOBEC3 enzymes induce chromosomal translocations in solid cancers.
Lionel Chia, MSc, Johns Hopkins University, Baltimore, Maryland. Abstract 297. HMGA1 induces FGF-19 to foster tumor-stromal cell crosstalk and drive tumor progression in pancreatic ductal adenocarcinoma.
Stephanie Chow, MD, Stanford University, Stanford, California. Abstract 5357. Total abdominal ultra-rapid FLASH irradiation enhances the efficacy of PD-1 inhibition in preclinical models of ovarian cancer.
Andrea Comba, PhD, University of Michigan Medical School, Ann Arbor, Michigan. Abstract 3950. Spatiotemporal analysis of gliomas: Dynamics of mesenchymal multicellular structures as novel target for tumor treatment.
Pedro Costa-Pinheiro, MSc, University of Virginia, Charlottesville, Virginia. Abstract 2079. Ceramide nanoliposomes a novel therapeutic option for androgen receptor-negative prostate cancer.
Burcu F. Darst, PhD, University of Southern California, Los Angeles, CA. Abstract 3517. A germline variant at 8q24 contributes to familial clustering of prostate cancer in men of African ancestry.
Pushpamali De Silva, MS, PhD, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts. Abstract 3853. The antitumor immune responses by active and quiescent tertiary lymphoid structures to breast cancer.
Huy Q. Dinh, PhD, La Jolla Institute for Immunology, La Jolla, California. Abstract 3311. B cell-like neutrophil found in peripheral blood of melanoma patients.
Daniel L. Doheny, MS, Wake Forest University, Winston-Salem, North Carolina. Abstract 5025. Antifungal ketoconazole inhibits tumor-specific transcription factor tGLI1 leading to suppression of breast cancer stem cells and brain metastasis.
Deniz N. Dolcen, BS, The University of Chicago, Chicago, Illinois. Abstract 1290. Role of NNMT-regulated m6A mRNA modification in triple-negative breast cancer oncogenic gene expression.
Marek M. Drozdz, PhD, Weill Cornell Medicine, New York, New York. Abstract 287. A nuclear cAMP microdomain suppresses tumor growth by Hippo pathway inactivation.
Grace Egan, MD, University Health Network, Toronto, Ontario, Canada. Abstract 3784. The metabolic enzyme Hexokinase 2 localizes to the nucleus and regulates stemness in AML through a kinase-independent mechanism.
Mitchell Fane, PhD, Johns Hopkins School of Public Health, Baltimore, Maryland. Abstract 6107. Stromal and immune changes in the aged lung microenvironment create a permissive niche for the metastatic outgrowth of melanoma.
Meghan C. Ferrall-Fairbanks, PhD, Moffitt Cancer Center and Research Institute, Tampa, Florida. Abstract 5490. Scales and dynamics of intratumor heterogeneity.
Marina G. Ferrari, BS, University of Minnesota, Minneapolis, Minnesota. Abstract 5014. Identifying and treating robo1-ve/dock1+ve prostate cancer: An aggressive cancer type highly prevalent in African-American patients.
Mona Foth, PhD, Huntsman Cancer Institute, Salt Lake City, Utah. Abstract 1225. Co-inhibition of autophagy and MAPK signaling in RAS-driven cancers.
Antonio Francavilla, MSc, Italian Institute for Genomic Medicine (IIGM), Candiolo (TO), Italy. Abstract 269. Small noncoding RNA profiling in stool and plasma samples to explore potential biomarkers for colorectal cancer diagnosis.
Alyssa V. Francis, BMSc, Goodman Cancer Research Centre, McGill University, Montréal, Québec, Canada. Abstract 1583. The tumor immune microenvironment in early breast cancer progression.
Benjamin C. Fu, PhD, MPH, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. Abstract 4648. Insulinemic and inflammatory dietary patterns and risk of prostate cancer.
Ting Fu, PhD, Salk Institute, San Diego, California. Abstract 396. The bile acid receptor FXR suppresses colitis-induced colon cancer.
Kavya Ganapathy, MS, University of Central Florida, Orlando, Florida. Abstract 274. Multifaceted function of microRNA-299-3p fosters an antitumor environment through modulation of androgen receptor and VEGFA signaling pathways in prostate cancer cells.
Aram Ghalali, PhD, Boston Children’s Hospital at Harvard Medical School, Boston, Massachusetts. Abstract 1822. RNA eding of AZIN1 increases cellular aggressiveness in prostate cancer.
Martina Ghetti, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST-IRCCS), Meldola, Italy. Abstract 260. Bromodomain and extraterminal motif proteins regulate linear and circular PVT1 in acute myeloid leukemia cells under normoxia and hypoxia.
Rashida A. Ginwala, PhD, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Abstract 6096. Bladder cancer microbiome and its association with chemoresponse.
Jordan M. Grainger, BA, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota. Abstract 1928. Study of copy number amplification and chemo-response in triple-negative breast cancer.
Kevin Hadi, MS, Weill Cornell Medical College, New York, New York. Abstract 825. Pan-cancer analysis of genome graphs reveals novel rearrangement patterns.
Amelia Hallas-Potts, BSc (Hons), University of Edinburgh, Edinburgh, United Kingdom. Abstract 2725. Long-term live imaging of ovarian cancer invasion using optical coherence tomography.
Sisi He, MSc, University of Illinois Urbana-Champaign, Urbana, Illinois. Abstract 2821. Cholesterol and its metabolism impact ovarian cancer progression.
Xin Hong, PhD, MGH Cancer Center/Harvard Medical School, Boston, Massachusetts. Abstract 6073. The lipogenic regulator SREBP induces Transferrin in circulating melanoma cells, suppressing their susceptibility to ferroptosis.
Jiaqi Huang, PhD, National Cancer Institute, Rockville, Maryland. Abstract 4658. Association of serum retinol with risk of overall and cause-specific mortality: A 30-year prospective cohort study.
Xiaomeng Huang, PhD, University of Utah, Salt Lake City, Utah. Abstract 1517. The integration of bulk DNA sequencing and single-cell analysis reveals diverse clonal evolution in CLL patients treated with BTKi.
Man Hsin Hung, MD, PhD, National Cancer Institute, Bethesda, Maryland. Abstract 1687. Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma.
Noor A. Hussein, MS, University of Toledo, Toledo, Ohio. Abstract 596. Endolysosomal trafficking defects leads to caspase-independent cell death in colon cancer.
Federica Iannelli, PhD, National Cancer Institute of Naples, “G. Pascale” Foundation, Naples, Italy. Abstract 5223. Valproic acid, by preventing cisplatin/cetuximab-induced EGFR nuclear translocation and increasing cisplatin uptake, potentiates the antitumor effect of the combination treatment in head and neck squamous cell carcinomas.
Claire L. Ihle, BA, University of Colorado Anschutz Medical Campus, Aurora, Colorado. Abstract 1580. Distinct pathways of lytic and blastic bone metastases in prostate cancer patients.
Payal Jain, PhD, Children’s Hopsital of Philadelphia, Philadelphia, Pennsylvania. Abstract 632. Novel BRAF gene fusions in pediatric histiocytic neoplasms respond differentially to RAF targeted therapies based on dimerization profiles.
Honglin Jiang, MD, PhD, University of California San Francisco, San Francisco, California. Abstract 6419. Novel ferrous iron-dependent prodrug strategy for KRAS-driven pancreatic cancer: The preclinic efficacy and safety test.
Robert T. Jones, BS, University of Colorado School of Medicine, Aurora, Colorado. Abstract 4091. Functional genomic screening in gemcitabine- and cisplatin-resistant bladder cancer cell lines identifies DNA repair pathways as mediators of chemosensitivity.
Linda Kachuri, PhD, University of California San Francisco, San Francisco, California. Abstract 2319. Pan-cancer analysis of polygenic risk scores reveals improvement in risk prediction and stratification.
Alexandra M. Kane, BS, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. Abstract 1103. Aspirin reduces the incidence of metastasis in a preclinical study of Braf mutant colorectal cancer.
Akash Kumar Kaushik, PhD, University of Texas Southwestern Medical Center, Dallas, Texas. Abstract 245. Glutamine fuels the TCA cycle in VHL and FH mutant renal cell carcinoma.
Homma M. Khosroyani, BS, Oregon Health and Science University, Portland, Oregon. Abstract 3005. Comprehensive profile of platelet-derived growth factor receptor alpha (PDGFRA) mutations in gastrointestinal stromal tumors.
Geffen Kleinstern, PhD, Mayo Clinic, Rochester, Minnesota. Abstract 1054. Vaccination history and risk of lymphoma and its major subtypes.
Brian S. Koss, BA, University of Arkansas for Medical Sciences, Little Rock, Arkansas. Abstract 1029. Epigenetic control of tumor-infiltrating lymphocyte metabolic exhaustion.
Edgar Ernesto Gonzalez Kozlova, PhD, Icahn School of Medicine, New York, New York. Abstract 3381. Identifying tumor antigen-specific CD4+ T cell dysfunctional states by single-cell transcriptomics in immunotherapy-treated cancer patients.
Chaoyuan Kuang, MD, PhD, University of Pittsburgh, Pittsburgh, Pennsylvania. Abstract 1763. NEO2734, a novel dual bromodomain and histone acetyltransferase inhibitor, in the treatment of colorectal cancer.
Arutha Kulasinghe, PhD, Queensland University of Technology, Brisbane, Queensland, Australia. Abstract 3384. Characterization of the tumor microenvironment and liquid biopsy in head and neck and non-small cell lung cancer.
Gaurav Kumar, PhD, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma. Abstract 1102. Model optimization and chemoprevention of IPMN-driven PDAC in KPSD4 mouse model.
Rajendra Kumar, PhD, Johns Hopkins University, Baltimore, Maryland. Abstract 2410. Supraphysiologic androgens induce ferroptotic cell death in prostate cancer cells.
Siyana Kurteva, MS, McGill University, Montreal, Quebec, Canada. Abstract 5769. Opioid prescription characteristics associated with frequent emergency department use among hospitalized cancer patients: A comparative cohort study.
Rui Li, MD, PhD, University of California Los Angeles, Los Angeles, California. Abstract 1016. Inhibition of chemokine-induced myeloid cells potentiates the anti-PD-1 response in KRAS/LKB1 mutant non-small cell lung cancer.
Sha Li, PhD, Sanford Burnham Prebys Medical Discovery Institute, San Diego, California. Abstract 3426. A synthetic lethality approach to eradicate AML via synergistic activation of proapoptotic p53 by MDM2 and BET inhibitors.
Zheqi Li, PhD, University of Pittsburgh, Pittsburgh, Pennsylvania. Abstract 4917. Estrogen receptor D538G mutation promotes cell migration via hyperactivation of Wnt signaling pathway.
Rossella Loria, PhD, Regina Elena National Cancer Institute, Rome, Italy. Abstract 1887. Tumor-stroma interactions mediated by Semaphorin 6A as a determinant of drug resistance in BRAF-mut melanoma.
Michael Marrone, PhD, MPH, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. Abstract 2357. Lipid-lowering drug use, duration of use, and age at first use is associated with a lower risk of colorectal cancer mortality in men and women in the Atherosclerosis Risk in Communities (ARIC) Study.
Rossella Marullo, MD, PhD, Weill Cornell Medicine, New York, New York. Abstract 1288. BCL6 drives an oncogenic transcriptional and epigenetic program in NSCLC whose inhibition results in antineoplastic activity in vivo.
Anna R. Michmerhuizen, BS, University of Michigan, Ann Arbor, Michigan. Abstract 6271. Hormone receptor inhibition as a strategy for radiosensitization of breast cancer.
Rachel L. Mintz, BS, Washington University in St. Louis, St. Louis, Missouri. Abstract 1158. Hormone gene expression and mammographic breast density in postmenopausal women.
Barbara Montico, PhD, Centro di Riferimento Oncologico di Aviano (CRO) IRCSS, Aviano, Italy. Abstract 1794. Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy.
David B. Morse, MPhil, University of Cambridge, Cambridge, United Kingdom; National Institutes of Health, Bethesda, Maryland. Abstract 5879. Spatially-segmented single-cell transcriptomics by diffusional accessibility to a small-molecule dye.
Justin T. Moyers, MD, Loma Linda University Cancer Center, Loma Linda, California. Abstract 4338. Immunotherapy in resected stage III melanoma: An analysis of the National Cancer Database.
Barzin Y. Nabet, PhD, Stanford University, Stanford, California. Abstract 5666. A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer.
Erisa Nita, MSc, University of Edinburgh, Edinburgh, United Kingdom. Abstract 3777. The role of IFITMs in maintaining glioma stem cells.
Athanasios Papadas, MD, University of California San Diego, La Jolla, California. Abstract 5733. Versican proteolytic fragments (matrikines) synergize with STING agonists to elicit robust antitumor CD8+ T-cell responses.
Abhijit Parolia, BS, University of Michigan, Ann Arbor, Michigan. Abstract 3437. Cistromically dominant class2 mutants of FOXA1 de-repress WNT signaling to drive prostate cancer metastasis.
Barbara Pasculli, PhD, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy. Abstract 1422. Clinical association of miR-155-5p with breast cancer and its relevance for treatment with PARP inhibitors.
Udara Perera, DrPH(c), MPH, Drexel University, Philadelphia, Pennsylvania; Harvard University, Boston, Massacusetts. Abstract 5736. Preventing liver cancer disparities: Knowledge, attitudes, and beliefs of childbearing women with hepatitis B.
Adam Pietrobon, BSc (Hons), Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. Abstract 6316. High-throughput small-molecule screening with synthetic 3D lung-mimetic hydrogels in the rare lung cancer lymphangioleiomyomatosis.
Vicente Planells-Palop, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts. Abstract 4903. Minimal mutational determinants of human squamous cell carcinoma.
Daniel R. Principe, MS, Wake Forest University, Winston-Salem, North Carolina. Abstract 955. Long-term gemcitabine treatment reshapes the pancreatic tumor microenvironment and sensitizes murine carcinoma to combination immunotherapy.
Cara A. Reiter-Brennan, IB Diploma, Charité-Universitätsmedizin, Berlin, Germany. Abstract 5773. Cardiorespiratory fitness and PSA screening patterns in the Henry Ford FIT Project.
Paula Restrepo, BA, Icahn School of Medicine at Mount Sinai, New York, New York. Abstract 1507. Regional DNA methylation profiling reveals novel epigenetic intratumoral heterogeneity signatures and aberrant molecular clocks in hepatocellular carcinoma.
Megan M. Richters, BS, Washington University School of Medicine, St. Louis, Missouri. Abstract 4727. Molecular heterogeneity in glioblastoma multiforme influences variant clonality and neoantigen prediction accuracy.
Andrea N. Riner, MD, MPH, University of Florida, Gainesville, Florida. Abstract 1172. Disparities in pancreatic ductal adenocarcinoma—the significance of Hispanic ethnicity, by subgroup analysis, and treatment facility on clinical outcomes.
Danja Sarink, PhD, University of Hawaii Cancer Center, Honolulu, Hawaii. Abstract 1169. Racial/ethnic differences in postmenopausal breast cancer incidence and risk factors: Results from the Multiethnic Cohort (MEC) Study.
Maria Stella Sasso, PhD, The University of Chicago, Chicago, Illinois. Abstract 1072. Lymphangiogenesis-inducing vaccines for melanoma treatment elicit potent tumor-specific T-cell immunity and long-term tumor control.
Sahil Seth, MS, The University of Texas MD Anderson Cancer Center, Houston, Texas. Abstract 1497. Longitudinal response and selection under neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized trial (ARTEMIS; NCT02276443).
Raef Shams, MS, RIKEN, Wako, Saitama, Japan. Abstract 662. A discovery of a small-molecule mTORC1 allosteric inhibitor targeting cancer cells.
Kamini Singh, PhD, Memorial Sloan Kettering Cancer Center, New York, New York. Abstract 1824. Coordinate translational control of the kras signaling pathway.
Vidya C. Sinha, PhD, The University of Texas MD Anderson Cancer Center, Houston, Texas. Abstract 2822. Single-cell evaluation to identify tumor-stroma niches driving the transition from in situ to invasive breast cancer.
Hannah L. Smith, MSc (Res), Newcastle University, Newcastle upon Tyne, United Kingdom. Abstract 1375. Investigating synergy between CHK1 and PARP inhibitors in BRCA2 mutant and restored cells.
Veena Somasundaram, PhD, National Cancer Institute, Frederick, Maryland. Abstract 2754. Inhibition of nitric oxide synthase and cyclooxygenase potentiates immune responses that control aggressive mammary tumor in a murine model.
Minkyo Song, MD, PhD, National Cancer Institute, Bethesda, Maryland. Abstract 1053. Associations of anti-parietal cell and anti-intrinsic factor antibodies with gastric cancer risk.
Rokana Taftaf, MS, MD, Northwestern University, Chicago, Illinois. Abstract 2603. Single-cell RNA sequencing-based identification of molecular drivers in circulating tumor cell cluster formation and lung metastasis.
Hideyuki Takahashi, MD, PhD, Gunma University, Maebashi, Japan. Abstract 1077. Macrophage PI3Kγ controls T-cell activation and T-cell memory generation through the production of IL-12.
Paulino Tallón de Lara, MD, PhD, Mount Sinai West; Mount Sinai St. Luke’s, New York, New York. Abstract 2646. CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer.
Sonia Tarallo, PhD, Italian Institute for Genomic Medicine (IIG), Turin, Italy. Abstract 257. Whole miRNome profiling in fecal and plasma exosome samples for the diagnosis of colorectal cancer.
Evgenii N. Tcyganov, PhD, The Wistar Institute, Philadelphia, Pennsylvania. Abstract 6615. Peroxynitrite mediates immune escape of tumor cells from cytotoxic T cells in situ.
Hideki Terai, MD, PhD, Keio University, Tokyo, Japan. Abstract 3081. SHOC2 is a critical modulator of the sensitivity to EGFR-TKI in non-small cell lung cancer cells.
Prashant Vijay Thakkar, PhD, Weill Cornell Medicine, New York, New York. Abstract 641. Systems biology identifies Gleevec as a specific inhibitor of CLIP-170S, a novel +TIP isoform, which causes taxane resistance in cancer cells and patients by obstructing the microtubule pore.
Daksh Thaper, PhD, University of British Columbia, Vancouver, British Columbia, Canada. Abstract 3083. Selective inhibition of transcription factor BRN2 as a treatment strategy for small-cell prostate cancer.
Isidora Tošić, MPharm, Dana-Farber Cancer Institute, Boston, Massachusetts. Abstract 6418. Targeting STAT3-driven breast cancer cells using layer-by-layer nanoparticles.
Aria Vaishnavi, PhD, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. Abstract 3769. Combined TRKA and MEK1/2 inhibition forestalls the onset of acquired resistance in a new preclinical model of NTRK1+ pancreatic cancer.
Georgii Vasiukov, PhD, Vanderbilt University Medical Center, Nashville, Tennessee. Abstract 1714A. TGF-beta signaling on myeloid cells regulates ECM deposition in mammary carcinoma via adenosine-dependent mechanisms.
Andrea Walens, PhD, University of North Carolina, Chapel Hill, North Carolina. Abstract 5389. Uncovering spatial relationships of the tumor microenvironment in the Carolina Breast Cancer Study.
Fei Wang, MD, PhD, Vanderbilt University Medical Center, Nashville, Tennessee. Abstract 1178. Racial/ethnic disparities in overall mortality among patients diagnosed with triple-negative breast cancer.
Fenglei Wang, ME, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. Abstract 1104. Folate intake and colorectal cancer risk during 36 years of follow-up in US women: A prospective cohort study.
Evan W. Warner, BSc, University of British Columbia, Vancouver, British Columbia, Canada. Abstract 3541. Biallelic alterations in BRCA2, ATM, or CDK12 in metastatic prostate cancer via circulating tumor DNA.
Justin S. Williams, PhD, St. Jude Children’s Research Hospital, Memphis, Tennessee. Abstract 6576. DNA methylation reveals alternative promoter usage in genes critical to pediatric tumors.
Juliane Winkler, PhD, University of California San Francisco, San Francisco, California. Abstract 351. Alterations in immune cell signatures during breast cancer metastasis at single-cell resolution.
Corrin Wohlhieter, BS, Weill Cornell Medicine, New York, New York. Abstract 1800A. STK11 and KEAP1 co-mutation cooperatively promotes rapid tumor growth in lung adenocarcinoma.
Meng-Ju Wu, PhD, Massachusetts General Hospital, Boston, Massachusetts. Abstract 1810. The mutant IDH1 inhibitor ivosidenib promotes tumor cell differentiation and antitumor immunity in intrahepatic cholangiocarcinoma.
You Wu, MS, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. Abstract 3471. Total red meat, unprocessed red meat, processed meat and risk of breast cancer—a pooled analysis of 23 cohort studies.
Guan-Yu Xiao, PhD, University of Texas Southwestern Medical Center, Dallas, Texas. Abstract 118. FCHSD2 controls oncogenic ERK1/2 signaling by regulating endocytic trafficking in non-small cell lung cancer.
Chun Philip Yeung, MSc, The Chinese University of Hong Kong, Hong Kong, China. Abstract 2345. Statin use associated with reduced risk of hepatocellular carcinoma recurrence following liver resection: A systematic review and meta-analysis.
Hyung-Suk Yoon, MPH, PhD, Vanderbilt University Medical Center, Nashville, Tennessee. Abstract 1052. Associations of Helicobacter pylori biomarkers with lung cancer risk among low-income and African American populations: Results from the Southern Community Cohort Study.
Yongji Zeng, Master of Medicine, University of Nebraska Medical Center, Omaha, Nebraska. Abstract 3691A. Targeting MARK2-HDAC-YAP signaling to overcome paclitaxel resistance in PDAC.
Baotong Zhang, PhD, Emory University, Atlanta, Georgia. Abstract 3840. KLF5 acetylation promotes bone metastatic growth of prostate cancer by activating CXCR4/IL-11 and subsequent osteoclast differentiation.
Jie Zhang, MS, Seoul National University, Seoul, South Korea. Abstract 3828. Tumor-promoting effects of sulforaphane on diethylnitrosamine-induced murine hepatocarcinogenesis.
Xiaotao Zhang, PhD, Baylor College of Medicine, Houston, Texas. Abstract 1121. Baseline oral microbiota profiles associated with all-cancer incidence in a cohort of nonsmoking Mexican American women.
Yin Zhang, MD, Brigham and Women’s Hospital; Dana-Farber Cancer Institute; Harvard Medical School, Boston, Massachusetts. Abstract 3392. Personal use of permanent hair dyes and cancer risk and mortality in US women: Prospective cohort study.
Jacquelyn W. Zimmerman, MD, PhD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland. Abstract 5716. miR-21 inhibition regulates mutant KRAS effector pathways and intercepts development of pancreatic ductal adenocarcinoma.
Qianying Zuo, MS, University of Illinois at Urbana-Champaign, Illinois. Abstract 5675. Metastatic organ-specific changes in ERα and XPO1 signaling and metabolic adaptations dictate the therapy responses in endocrine-resistant breast cancers.